FIT Cancer 11 11th FORUM ON Translational Immunology and IMMUNOTHERAPY OF CANCER 16 CP-16. METABOLIC TUMOR ASSESSMENT IN ONCOLOGIC IMMUNOTHERAPY: THE ROLE OF 18FFDG PET-CT Henry Diego Patty Flores1, Mayra Victoria Choque Plata2 1Red de Centros de Medicina Nuclear y Radioterapia (CMNYR). La Paz, Bolivia. 2Victoria Medicina. La Paz, Bolivia CP-17. MANAGEMENT OF SEVERE IMMUNOTHERAPY-RELATED MYOCARDITIS, MYOSITIS AND MYASTHENIA GRAVIS (MMM) OVERLAP SYNDROME GUIDED BY PATIENT’S IMMUNE PRPOFILE: A CASE REPORT Alberto Torres Zurita, María del Carmen Álamo de la Gala, Luis de la Cruz Merino Hospital Universitario Virgen Macarena. Sevilla CP-18. IMMUNOTHERAPY IN METASTATIC COLORECTAL CANCER: A POOR-PROGNOSIS CASE WITH COMPLETE RESPONSE TO PEMBROLIZUMAB IN ADVANCED LINES Alfonso Bravo Aguilar, Raúl Rodríguez León, Marta Espinosa Montaño Hospital Universitario Virgen Macarena. Sevilla CP-19. EFFECTIVENESS OF IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH ACRAL LENTIGINOUS MELANOMA IN THE ADJUVANT AND METASTATIC SETTING, EXPERIENCE OF A SINGLE CENTER Jorge Alonso Zegarra Cárdenas, Marian Gheraldine Mendoza Castillón IREN Centro. Concepción, Perú 11:45-12:45 Session III: Antibody-drug conjugates in cancer immunotherapy Chairs: Dra. Cristina Suárez Rodríguez Hospital Universitari Vall d’Hebron. Barcelona Dr. Xabier Mielgo Rubio Hospital Universitario Cruces. Bilbao 11:45-12:00 Update in clinical development of novel bi/multispecifics: the revolution continues Dra. María de Miguel-Luken START Madrid. Centro Integral Oncológico Clara Campal - CIOCC. Hospital Universitario HM Sanchinarro. Madrid 12:00-12:15 ADC and immunotherapy: stronger together? Dr. Ángel Guerrero Zotano Instituto Valenciano de Oncología. Valencia 12:15-12:30 Biomarkers in ADCs: can we personalize ADC-based therapies? Dr. Federico Rojo Todo Hospital Universitario Fundación Jiménez Díaz. Madrid 12:30-12:45 Discussion ❚ Discusión
RkJQdWJsaXNoZXIy OTI4NTYw